Expanding access to and uptake of PrEP products among young people, especially adolescent girls and young women, will be key to ending the HIV epidemic. But how do we ensure HIV prevention efforts resonate with and are effective for young millennials and Gen Z? What does meaningful youth engagement in PrEP delivery really mean?

This IAS 2023 session will review evidence from recent studies designed to inform CAB PrEP introduction in Asia; identify regional priorities for a CAB implementation science agenda; examine regional lessons from oral PrEP introduction and scale-up; highlight progress and lessons from preparing for CAB rollout in Africa; and introduce available policy and program planning tools and resources to help countries prepare for CAB rollout.

MOSAIC is heading to Durban, South Africa, for the 11th SA AIDS conference. This year’s conference theme: Act, connect, and end the epidemic. We invite conference attendees to join us for the following sessions.

As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings.

New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.